Compounded semaglutide vs brand-name semaglutide — what you need to know.
What compounded semaglutide is, how it is legally compounded under 503A authority, 503A vs 503B pharmacy standards, quality markers to verify, and how it compares molecule-for-molecule to brand-name formulations.
What is compounded semaglutide?
Compounded semaglutide is the same active pharmaceutical ingredient — semaglutide — prepared by a licensed compounding pharmacy rather than manufactured by the manufacturer. The molecule is identical: a 31-amino-acid GLP-1 receptor agonist with a C-18 fatty acid chain that extends its half-life to approximately 7 days.
Compounding pharmacies purchase pharmaceutical-grade semaglutide base powder from FDA-registered suppliers and reconstitute it into injectable formulations under sterile conditions. When prescribed for a documented clinical need, compounded semaglutide is a legally produced medication prepared under 503A compounding authority.
Why compounded semaglutide is legal
Under Section 503A of the Federal Food, Drug, and Cosmetic Act, licensed compounding pharmacies may prepare compounded versions of FDA-approved medications when those medications are on the FDA Drug Shortage Database. Semaglutide was listed as "in shortage" from 2022 until February 2025, when the FDA declared the shortage resolved. However, 503A compounding remains available for patient-specific prescriptions where a prescriber documents that the commercially available product does not meet the patient's clinical needs.
503A pharmacies may compound semaglutide when a prescriber identifies a specific clinical reason the commercially available product is not appropriate — such as the need for a custom dose, an allergen-free formulation, or a concentration not commercially available. This is standard 503A compounding authority under federal law.
503A vs 503B compounding pharmacies
503A pharmacies (patient-specific)
Most common for compounded semaglutide. They prepare medications based on individual prescriptions, are licensed by the state board of pharmacy, and must comply with USP 797 sterile compounding standards for injectables.
503B outsourcing facilities
Can compound without patient-specific prescriptions in larger batches. Registered with the FDA, subject to FDA inspection, and must follow cGMP standards. Typically used by clinics that dispense on-site.
Compounded vs brand-name semaglutide
| Feature | Brand (diabetes) | Brand (weight loss) | Compounded |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| Indication | Type 2 diabetes | Weight management | Per prescriber |
| Doses available | 0.25–2.0 mg | 0.25–2.4 mg | Any dose (custom) |
| Delivery | Pre-filled pen | Pre-filled pen | Vial + syringe |
| Monthly cost | $900–$1,000+ | $1,349 list | $150–$400 |
| Availability | Intermittent shortage | Intermittent shortage | Availability varies |
Quality and purity
Legitimate compounding pharmacies source pharmaceutical-grade semaglutide base from FDA-registered bulk suppliers. Each batch should include a Certificate of Analysis (CoA) verifying identity, purity, potency, and sterility. Key quality markers:
- State board of pharmacy license — verify the pharmacy is licensed in its state
- USP 797 compliance — required for sterile injectable compounding
- Third-party testing — independent potency and sterility verification
- PCAB accreditation — voluntary accreditation indicating higher standards
- Beyond-use dating — clear expiration dates based on USP stability guidelines
Semaglutide salt forms — important distinction
Some compounded semaglutide is prepared as semaglutide sodium or semaglutide acetate rather than the base form used in brand-name products. The FDA has stated semaglutide sodium is a different salt form and has taken enforcement action against some pharmacies using it. Legitimate 503A pharmacies should compound with semaglutide base — the same form used in brand-name semaglutide. Ask your pharmacy to confirm.
What happens when the shortage ends?
The FDA declared the semaglutide shortage resolved in February 2025. The shortage-based compounding exemption has ended. However, 503A pharmacies continue to compound semaglutide under traditional compounding authority when a prescriber documents that the commercially available product does not meet the patient's individual clinical needs. Multiple federal court challenges to the FDA's shortage determination remain ongoing as of April 2026.